CN205095072U - Artificial biological blood vessel with valve - Google Patents
Artificial biological blood vessel with valve Download PDFInfo
- Publication number
- CN205095072U CN205095072U CN201520815891.6U CN201520815891U CN205095072U CN 205095072 U CN205095072 U CN 205095072U CN 201520815891 U CN201520815891 U CN 201520815891U CN 205095072 U CN205095072 U CN 205095072U
- Authority
- CN
- China
- Prior art keywords
- valve
- blood vessel
- glutaraldehyde
- tannic acid
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The utility model discloses an artificial biological blood vessel with valve, artificial biological blood vessel with valve includes: one section blood vessel that has a natural valve of handling through tannin crosslinked processing step, have wrap -around medical macromolecular materials layer outside the hematal valve position of natural valve, with the blood flow direction indication arrow point that made up on the surface on medical macromolecular materials layer.
Description
Technical field
This utility model belongs to biomedical engineering field, relates to a kind of artificial bio-membrane and is with valve blood vessel, particularly relates to a kind of for the artificial bio-membrane's valved conduit rebuild with repair right ventricle-pulmonary artery and be connected.
Background technology
China's congenital heart disease rate is about 6 ‰-9 ‰, occupies the first place of birth defect, and an annual new children with CHD about 200,000, existing children with CHD is more than 2,000,000, and wherein congenital heart disease accounts for 20%.Quite a few complicated congenital heart disease pathological changes involves right ventricular outflow, as serious method Lip river tetrad, D-transposition of conducting arteries, truncus arteriosus communis, double outlet of right ventricle and pulmonary atresia etc.Application band valve pipeline is set up or recovers right ventricular outflow-pulmonary artery seriality, be one of ordinary operation of the above-mentioned heart malformations of surgical correction, be widely used at present in many congenital heart disease right ventricular outflow tract reconstructions and Ross operation (rose's operation).
The clinical efficacy of right ventricular outflow tract reconstruction art and the kind of valved conduit material selected by it and performance closely related.Existing polytype valved conduit material sequential use was in clinical in the past, comprised synthetic material pipeline, porcine aortic valve or valve of pulmonary trunk pipeline, pericardium pipeline etc.But be limited by the limitation of material itself, the clinical efficacy of existing valved conduit is not very good, fails to meet clinical demand completely, lobe leaf as bovine pericardium and pig heart valve is thicker, quality is partially hard, needs larger pressure that valve is fully opened, is not suitable for the lower pressure environment of Venous system; Pericardial tissue is in threadiness, and the lobe leaf of pericardium material is easy to wear.
In recent years, bovine jugular vein because of have natural SANYE valve structure, anti-reflux functional, be applicable to the human body right side and feel concerned about the advantages such as the lower pressure environment of system, source be sufficient and become department of cardiac surgery outflow tract of right ventricle gradually and rebuild one of substitution material, have a extensive future.The Contegra pipeline that Medtronic Inc. of the U.S. adopts conventional cross-linking agent glutaraldehyde to fix bovine jugular vein is the current Valved bovine jugular vein product uniquely obtaining U.S. FDA (U.S. food Drug Administration) and ratify to come into the market.Although this product have haemodynamic function good, be easy to surgical procedures and the advantage such as source is sufficient and be in absolute monopoly status in the world, but because China is to the limiting factor of overseas cattle source biological product, this product fail always at home market application, in addition to there is no similar commercially produced product available in domestic market, and therefore bovine jugular vein pipeline material fails formally to apply in China's department of cardiac surgery field.In addition, increasing clinical practice recently shows that Contegra pipeline exists tubal wall calcify at a specified future date, distal anastomosis stenostomy and pipeline Ectasia and causes the problems such as pipeline mistake merit decays.
Above-mentioned complication may be relevant with glutaraldehyde process, and glutaraldehyde has it self shortcoming as foreign material cross-linking agent.First, it has certain crosslinked action to collagen fiber, but to other component if elastic fiber and proteoglycan etc. are without crosslinked action; The second, it easily causes calcium deposition and calcification in biological tissue.The tissue of calcification can hardeningly become fragile, the activity of impact tissue is also easily torn, is bored a hole, and cause biomaterial poor durability, patient must accept second operation and be taken out by the tissue of calcification, so not only there is certain danger, and add unnecessary misery to patient.The biomaterial calcification how alleviating glutaraldehyde cross-linking is the key content that recent two decades carrys out people's research, from removing the lipid, the cell debris that cause calcification tissue, in neutralization tissue, remaining glutaraldehyde and Competitive assays Calcium-ion absorption angularly also have found some effective processing methods, but its complicated operation, and its long-term effect still under observation.
Tannic acid (tannicacid, TA) is a kind of plant polyphenol (also known as acid of trampling in pharmacopeia), belongs to galloyl-glucose family, its good water solubility, and suitable dosage is to the effect of human non-toxic's evil.In recent years, tannic acid is used for the preparation of foreign material gradually at biomedical engineering field.Tannic acid stablizes elastic fibers etc. by hydrogen bonded.Bovine jugular vein tube wall is containing a large amount of elastic fibers (being mainly distributed in tube wall subintima and middle level), and elastic fibers degraded can cause tube wall Ectasia to change and calcification.Tannic acid modification is carried out to the Valved bovine jugular vein fixing through glutaraldehyde, is expected to improve its calcification performance.
In addition, also find in our experimentation, the elasticity of bovine jugular vein blood vessel wall is larger, tensile energy is more weak, if do not use restraint to valve place tube wall, for the patient that pulmonary artery pressure is higher, there is tube wall overdistension and the risk causing valvular insufficiency, backflow.
Utility model content
The purpose of this utility model is, provides a kind of biocompatibility and calcification is functional, reasonable in design, tensile energy are comparatively strong, operation technique is easy artificial bio-membrane is with valve blood vessel.
This utility model provides a kind of artificial bio-membrane to be with valve blood vessel, and described artificial bio-membrane is with valve blood vessel to comprise:
One section of blood vessel with natural valve through the process of tannic acid crosslinking treatment step;
At the medical macromolecular materials layer of the valve site outer cladding of the described blood vessel with natural valve;
With
At the blood flow direction arrow that the surface of described medical macromolecular materials layer is made.
Selectively, the described vessel origin with natural valve in quadruped arteries or vein blood vessel, comprising one or more valve.
Selectively, described vein blood vessel is bovine jugular vein, has complete natural valve structure, comprising two lobe impeller structures or three lobe impeller structures.
Selectively, described bovine jugular vein length is 4-16cm, and diameter is 6-28mm.
Selectively, described medical macromolecular materials layer adopts the mode of silk sutures or biological adhesive bonding to be coated on outside the described valve site with the blood vessel of natural valve.
Selectively, described medical macromolecular materials layer is medical braided polyester thing.
Selectively, described braided polyester thing covers the described length with the blood vessel of natural valve is 1.5-6cm.
Selectively, described blood flow direction arrow is formed by medical sutures sewer.
Wherein, described tannic acid cross-linking treatment method comprises the blood vessel used with natural valve described in tannic acid solution immersion.In one embodiment, described tannic acid solution dissolves preparation by He Peisi liquid (Hepes liquid) or phosphate buffer, concentration is 0.1-0.6% mass volume ratio, pH value is 4.0-7.0 (wherein 5.5-6.0 is good), cross linking conditions is that at 18-40 DEG C, 24-96 hour is soaked in 0-200 rpm (rpm) shake, and the amount that tannic acid solution is no less than 5mL with every centimetre of length of vessel correspondence uses.In another specific embodiment, described tannic acid solution is the mixed liquor of tannic acid and glutaraldehyde, tannic acid concentration is 0.1-0.6% mass volume ratio, and glutaraldehyde concentration is 0.2-1.0% mass volume ratio, dissolves preparation by He Peisi liquid (Hepes liquid) or phosphate buffer.
Wherein, the glutaraldehyde solution using He Peisi liquid (Hepes liquid) to dissolve can be comprised before described tannic acid crosslinking treatment step and process is fixed to the described blood vessel with natural valve.In one embodiment, described glutaraldehyde is fixed treatment step and is comprised: the glutaraldehyde solution that (1) working concentration is 0.5-1.0%, pH value is 5.0-8.0 soaks the described blood vessel with natural valve, soaking temperature is 4-25 DEG C, and soak time is 2 days; (2) step (1) gained blood vessel is re-used the glutaraldehyde solution that concentration is 0.2-0.5%, pH value is 5.0-8.0 to soak, soaking temperature is 4-25 DEG C, and soak time is more than 7 days.The concentration of described He Peisi liquid (Hepes liquid) is 30-50mM (wherein 50mM is good), and pH value is 5.0-7.4.
Tannic acid described in the utility model is a kind of plant polyphenol, containing multiple hydrophilic residue on its molecular structure, can be specifically bound to the hydrophobic region of proline rich albumen (as collagen protein and elastin laminin) and form multiple hydrogen bond.Tannic acid is by compositions such as collagen fabric, elastin fiber and the mucopolysaccharides in these hydrogen bond stabilizing tissue Materials Cell epimatrixs, can significantly reduce the calcification caused by mass degradations such as elastic fibers mucopolysaccharides on the one hand, the biomechanical property of material can also be improved on the one hand, strengthen fatigue resistance, thus extend the service life in vivo of material.In addition, tannic acid also has effect that is antibacterial and minimizing protein antigenicity, and these characteristics also contribute to calcification performance and the biocompatibility of reinforcing material.
Glutaraldehyde cross-linking technique for fixing is now widely used in cardiovascular embedded material, the action site of the site of its crosslinked action just in time quiet acid with tannin is complementary, the type of bonding is also different, so when using glutaraldehyde and tannic acid is worked in coordination with crosslinked, collagen protein on glutaraldehyde cross-linking organization material, and the collagen protein while of tannic acid on crosslinked tissue material, play azelon and proteoglycan, compensate for the deficiency of glutaraldehyde cross-linking, the various component of material all obtains and is effectively cross-linked, cross-bond is except hydrogen bond, also has covalent bond, the forms such as complex bonds, crosslinking Treatment is worked in coordination with owing to using tannic acid and glutaraldehyde, the bonding degree of material and mechanical property all have raising by a relatively large margin, not easily by the enzymatic degradation in host tissue after implanting, decrease the quantity of elastin degradation, thus reduce the calcification potential of material, also can play the effect that glutaraldehyde removes tissue antigen and sterilization simultaneously.
This utility model provides a kind of artificial bio-membrane to be with valve blood vessel, comprises one section of blood vessel with natural valve through the process of described tannic acid crosslinking treatment step; At the medical macromolecular materials layer of the valve site outer cladding of the described blood vessel with natural valve; With the blood flow direction arrow that the surface at described medical macromolecular materials layer is made.
Wherein, described natural valve answers that structural integrity, form are good, size is even, and can be two lobe impeller structures, also can be three lobe impeller structures.
Wherein, the described blood vessel with natural valve can be prepared from by the blood vessel comprising one or more valve, can be arteries, also can be vein blood vessel.The quadruped jugular vein blood vessels such as cattle, horse, goat, sheep can be adopted, preferred bovine jugular vein blood vessel.Described bovine jugular vein length is 4-16cm, and diameter is 6-28mm.
Wherein, described medical macromolecular materials layer can adopt the mode of silk sutures or biological adhesive bonding to be coated on outside the described valve site with the blood vessel of natural valve.
Wherein, described medical macromolecular materials layer can be medical braided polyester thing, evenly, is entirely coated on valve outside, does not change the internal diameter of blood vessel and the opening and closing of lobe leaf.Coated length is generally 1.5-6cm, ensures that lobe hole normal turgor again can not overdistension, thus effectively keeps the morphology and function of valve, make it tolerate higher blood pressure.
Wherein, described blood flow direction arrow can be formed by medical sutures sewer, and blood vessel outflow end is all pointed at the tip of arrow.Described blood flow direction arrow can comprise open line style arrow, open Dotted arrows and closed type line style arrow.
As from the foregoing, the utility model has the advantages that: (1) tannic acid crosslinking Treatment technology, strengthen biological tissue's mechanical strength and stability, and improve calcification performance; (2) natural valve structure, has good hemodynamic performance and anti-reflux performance; (3) cover medical macromolecular materials layer outside the valve site of blood vessel, restriction lobe hole overdistension, effectively can keep the morphology and function of valve, make it tolerate higher blood pressure; (4) design of blood flow direction arrow, can mark blood flow direction during valve duty intuitively, is convenient to the direction recognizing blood vessel and valve in art quickly and accurately.
Accompanying drawing explanation
Fig. 1 is this utility model structural representation;
Fig. 2 A is this utility model sectional structure schematic diagram, and wherein, valve is open mode;
Fig. 2 B is this utility model sectional structure schematic diagram, and wherein, valve is closure state;
Fig. 3 A, 3B, 3C, 3D are the embodiment schematic diagram of blood flow direction arrow described in the utility model;
Laying state schematic diagram during Fig. 4 A reconstruction operations that to be this utility model connect for right ventricle-pulmonary artery;
Fig. 4 B is this utility model laying state schematic diagram when performing the operation for Ross;
Fig. 4 C is that this utility model is with laying state schematic diagram during the prosthesis of being with valve sticking patch form for right ventricle-pulmonary artery connection.
Main element and symbol description: 1, with the blood vessel of natural valve; 2, medical macromolecular materials layer; 3, blood flow direction arrow; 4, natural valve; M, blood vessel flow into end; N; Blood vessel outflow end.
Detailed description of the invention
This utility model comprises the preparation method of a kind of artificial bio-membrane with valve blood vessel, the method comprises the step using tannic acid solution as cross-linking agent, the biological tissue of described artificial bio-membrane with valve blood vessel to be carried out to crosslinking Treatment, and can comprise the step using glutaraldehyde solution described biological tissue to be fixed to process before described tannic acid crosslinking treatment step.
In one embodiment, preparation method of the present utility model mainly comprises the fixing process of glutaraldehyde and tannic acid crosslinking treatment step, and concrete steps are as follows:
(1) get the long fresh bovine jugular vein blood vessel of about 13cm and (remove the foreign material such as fat, and use the isosmotic solution such as normal saline or Hank ' s liquid to rinse well), in tube chamber, 0.6% glutaraldehyde solution (mass volume ratio is injected from blood vessel outflow end, prepared by He Peisi liquid (HEPES liquid), pH7.4), make lobe leaf be closure state, tube wall keeps some tension, this blood vessel end of ligation; Re-use same solution and fill the another side pipe chamber (in holding chamber no-station pole canopy) of this blood vessel valve, this blood vessel end of ligation; Finally be soaked in same solution completely by the blood vessel of full full solution, fix 48 hours at 4 DEG C, every root blood vessel correspondence is no less than 0.6% glutaraldehyde solution of 100mL.
(2) blood vessel of step (1) gained is taken out, unclamp blood vessel two ends ligature, remove pipe intracavity liquid, adopt the method for step (1), 0.3% glutaraldehyde solution (mass volume ratio is prepared by He Peisi liquid (HEPES liquid), pH7.4) is injected in tube chamber, and blood vessel is soaked in completely in same solution, fix more than 7 days at 4 DEG C.
(3) blood vessel of step (2) gained is taken out, remove pipe intracavity liquid, pruning blood vessel two end makes length of vessel be 10cm, blood vessel is soaked in completely 0.3% tannic acid solution (mass volume ratio, by phosphate buffered saline) in, keep in Dark Place at 18-25 DEG C 4 days.
In our study, the bovine jugular vein of above-mentioned specific embodiment (comprising the fixing process of glutaraldehyde and tannic acid crosslinking treatment step) gained is designated as glutaraldehyde/tannic acid group, the bovine jugular vein blood vessel only carrying out glutaraldehyde and fix treatment step is designated as glutaraldehyde group, and from the following aspects, comparative study has been carried out to two groups of samples:
1. outward appearance
Glutaraldehyde group bovine jugular vein is faint yellow, and glutaraldehyde/tannic acid group is light brown, and its tube wall comparatively glutaraldehyde group is slightly hard, two groups of bovine jugular vein valves are all soft, and mobility is also without obviously distinguishing.
2. the hot shrinkage temperature of tube wall
As shown in table 1, the a little higher than glutaraldehyde group of glutaraldehyde/tannic acid group bovine jugular vein pipe wall material hot shrinkage temperature, statistical analysis display difference significance (P < 0.01), illustrates that tannic acid crosslinking Treatment can strengthen the heat stability of the bovine jugular vein blood vessel fixed through glutaraldehyde further.
Table 1 glutaraldehyde group and glutaraldehyde/tannic acid group bovine jugular vein tube wall
Hot shrinkage temperature
*P＜0.01
3. tube wall hot strength and elongation at break
As being shown in Table 2, glutaraldehyde/tannic acid group bovine jugular vein tube wall compares with glutaraldehyde group, its tensile strength, elongation at break all increase (P < 0.05), illustrate that tannic acid crosslinking Treatment can strengthen the physical strength of the bovine jugular vein blood vessel fixed through glutaraldehyde further.
The ultimate tensile strength of table 2 glutaraldehyde group and glutaraldehyde/tannic acid group bovine jugular vein tube wall and elongation at break
*P＜0.01，
#P＜0.05
4. the test of anticol fibril enzymatic degradation and Elastase Degrading experiment
Bovine jugular vein tube wall row collagen fiber enzymatic degradation and the Elastase Degrading experiment respectively of glutaraldehyde group and glutaraldehyde/tannic acid group, being accounted for by enzymolytic tissue organizes total weight percent in table 3, point out the resistance to enzymolysis ability of glutaraldehyde/tannic acid group bovine jugular vein tube wall higher than glutaraldehyde group, statistical analysis significance (P < 0.01).
Accounted for the percentage ratio of gross weight by enzymolytic tissue after table 3 glutaraldehyde group and glutaraldehyde/tannic acid group bovine jugular vein tube wall enzymatic degradation
*P＜0.01，
#P＜0.01
5. subcutaneous rat heeling-in experiment
Through subcutaneous rat heeling-in after 21 days and 60 days, glutaraldehyde group bovine jugular vein tube wall is hardening, become fragile, and the visible tube chamber face of sample segment naked eyes exists calcification (especially heeling-in is after 60 days); And glutaraldehyde/tannic acid group bovine jugular vein tube wall is soft, naked eyes have no any calcification, darken.
ET ten VG dyes display, glutaraldehyde group bovine jugular vein tube wall through subcutaneous rat heeling-in elastic fibers disintegrate fracture in tube wall after 21 days, arrangement disorder; After 60 days, this group elastic fibers destructiveness is more obvious.On the contrary, in glutaraldehyde/tannic acid group, in bovine jugular vein tube wall, elastic fibers is all substantially intact at 21 and 60 days two time points.Vascular wall tissue elastin laminin quantitative analysis display glutaraldehyde group elastin laminin is lost obviously.Result shows that glutaraldehyde can not fix bovine jugular vein tube wall elastic fibers, and tannic acid can protect elastic fibers effectively, to exempt its degradation in vivo.
Masson dyes display, and two groups of bovine jugular vein tube walls are in subcutaneous rat heeling-in after 21 days, and collagen fiber structure is preserved complete substantially; At the 60th day, glutaraldehyde group collagen fiber structure was disorderly, and glutaraldehyde/tannic acid group remains unchanged.Result prompting tannic acid crosslinking Treatment contributes to stable bovine jugular vein tube wall collagen fiber structure.
VanKossa coloration result shows, through subcutaneous rat heeling-in after 21 days and 60 days, glutaraldehyde group bovine jugular vein tubal wall calcify is obvious, and in time dependence, and glutaraldehyde/tannic acid group tube wall has no calcification on the 21st day in heeling-in, within the 60th day, only see that trace is dispersed in calcification point; Calcium quantitative analysis results is consistent with VanKossa coloration result, illustrates that bovine jugular vein tube wall that tannic acid crosslinking Treatment can prevent glutaraldehyde fixing is effectively in body calcification.In addition, glutaraldehyde group calcification is overlapping with elastic fibers locus, and both promptings are closely related.
This utility model comprises a kind of artificial bio-membrane and is with valve blood vessel, and this blood vessel comprises: one section of blood vessel with natural valve through the process of described tannic acid crosslinking treatment step; At the medical macromolecular materials layer of the valve site outer cladding of the described blood vessel with natural valve; With the blood flow direction arrow that the surface at described medical macromolecular materials layer is made.
Refer to Fig. 1, for artificial bio-membrane described in the utility model is with the structural representation of valve blood vessel.Artificial bio-membrane comprises with valve blood vessel the blood vessel 1 that a length of tape has natural valve 4, the valve site of blood vessel sews up medical macromolecular materials layer 2 outward, medical macromolecular materials layer surface is sewed with blood flow direction arrow 3, and blood vessel outflow end N is pointed at arrow tip, and the other end is that blood vessel flows into end M.
Blood vessel 1 with natural valve 4 has complete natural valve structure, is prepared from by after the chemical modification of the blood vessel comprising one or more valve.Excess tissue and valve should be removed during preparation, only retain the blood vessel wall of one group of structural integrity, good, the of uniform size valve of form and certain length.This valve can be two lobe impeller structures, also can be three lobe impeller structures; This blood vessel can be arteries, also can be vein blood vessel.Vein blood vessel can adopt the quadruped jugular vein blood vessels such as cattle, horse, goat, sheep, generally, conventional with bovine jugular vein blood vessel.During concrete enforcement, can determine according to the length of the corresponding blood vessel of patient's valve diseased region and diameter with the length of the blood vessel 1 of natural valve 4 and diameter, normal length is 4-16cm, and diameter is 6-28mm.
Medical macromolecular materials layer 2 can select medical braided polyester thing, adopt the mode sewed up or bond, evenly, valve 4 is entirely coated on outside, coated length is generally 1.5-6cm, ensure that lobe hole normal turgor again can not overdistension, thus effectively keep the morphology and function of valve, make it tolerate higher blood pressure.Referring to Fig. 2 A-2B, is sectional structure schematic diagram of the present utility model.Under normal blood flow direction, valve is fully opened, and blood flow moves smoothly through valve (Fig. 2 A); Under less reflux pressure, valve is completely closed, blood engorgement whole lobe hole inner chamber, and the blood pressure of rising makes lobe hole start expansion, but medical macromolecular materials layer 2 limits its overdistension, avoids being caused by valvular insufficiency backflow (Fig. 2 B).
Referring to Fig. 3 A-3D, is the detailed description of the invention schematic diagram of blood flow direction arrow 3 described in the utility model.Blood flow direction arrow 3 is formed by medical sutures sewer, and mode of appearance comprises open line style arrow (Fig. 3 A, 3B), open Dotted arrows (Fig. 3 C) and closed type line style arrow (Fig. 3 D).Wherein Dotted arrows can adopt the mode of knotting to make, and stitching thread also can be adopted to shuttle back and forth in the inside of medical macromolecular materials layer 2 and outside and make.In the various embodiments described above, blood vessel outflow end N is all pointed at the tip of arrow, marks blood flow direction during valve duty intuitively, is convenient to the direction recognizing blood vessel and valve in art quickly and accurately.
Refer to Fig. 4 A-4C, for this utility model for performing the operation time laying state schematic diagram.In the operation of rebuilding right ventricle-pulmonary artery connection, inflow end M of the present utility model and right ventricular outflow are exported and coincide, outflow end N and pulmonary trunk coincide (Fig. 4 A).In Ross operation, after autologous patient valve of pulmonary trunk is implanted to aortic valve position together with part pulmonary artery, then inflows of the present utility model end M, outflow end N are exported with right ventricular outflow respectively, pulmonary trunk identical (Fig. 4 B).In addition, by longitudinal for this utility model cutting, remove unwanted lobe leaf and blood vessel wall, repair right ventricle-pulmonary artery with the form with valve sticking patch and connect, farthest can retain the valve of pulmonary trunk (Fig. 4 C) of patient self.
The above, only by way of example in this utility model preferably embodiment be described, be not intended to limit scope of patent protection of the present utility model.Every utilize this utility model description and accompanying drawing content to do equivalent structure or the conversion of equivalent flow process, or be directly or indirectly used in other relevant technical fields, be all in like manner included in scope of patent protection of the present utility model.
Claims (4)
1. artificial bio-membrane is with a valve blood vessel, it is characterized in that, described artificial bio-membrane is with valve blood vessel to comprise:
One section of blood vessel with natural valve through the process of tannic acid crosslinking treatment step;
At the medical macromolecular materials layer of the valve site outer cladding of the described blood vessel with natural valve; With
At the blood flow direction arrow that the surface of described medical macromolecular materials layer is made.
2. artificial bio-membrane as claimed in claim 1 is with valve blood vessel, it is characterized in that, the described vessel origin with natural valve in quadruped arteries or vein blood vessel, comprising one or more valve.
3. artificial bio-membrane as claimed in claim 2 is with valve blood vessel, and it is characterized in that, described vein blood vessel is bovine jugular vein, and described vein blood vessel has complete natural valve structure, comprising two lobe impeller structures or three lobe impeller structures.
4. artificial bio-membrane as claimed in claim 1 is with valve blood vessel, and it is characterized in that, described blood flow direction arrow is formed by medical sutures sewer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520815891.6U CN205095072U (en) | 2015-10-19 | 2015-10-19 | Artificial biological blood vessel with valve |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520815891.6U CN205095072U (en) | 2015-10-19 | 2015-10-19 | Artificial biological blood vessel with valve |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205095072U true CN205095072U (en) | 2016-03-23 |
Family
ID=55510888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520815891.6U Active CN205095072U (en) | 2015-10-19 | 2015-10-19 | Artificial biological blood vessel with valve |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205095072U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017067295A1 (en) * | 2015-10-19 | 2017-04-27 | 北京迈迪顶峰医疗科技有限公司 | Artificial biological blood vessel having valve and preparation method thereof |
| CN113952513A (en) * | 2021-11-29 | 2022-01-21 | 四川大学华西医院 | Anti-aging artificial biological valve and preparation method and application thereof |
-
2015
- 2015-10-19 CN CN201520815891.6U patent/CN205095072U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017067295A1 (en) * | 2015-10-19 | 2017-04-27 | 北京迈迪顶峰医疗科技有限公司 | Artificial biological blood vessel having valve and preparation method thereof |
| CN113952513A (en) * | 2021-11-29 | 2022-01-21 | 四川大学华西医院 | Anti-aging artificial biological valve and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2725723C2 (en) | Warp knitted fabric and medical material | |
| JP5050197B2 (en) | Production method of biological scaffold | |
| ES2639424T3 (en) | Method for preparing stiff edge artificial biological valve | |
| JP5002805B2 (en) | Production method of biological scaffold | |
| CN108578781B (en) | Swim bladder source biological valve material and preparation method and application thereof | |
| WO2013182171A1 (en) | A method of constructing a pericardial heart valve replacement, a pericardial heart valve replacement constructed according to this method, and a device for the in vitro conditioning and modification of tissue of autologous pericardium for the construction of a pericardial heart valve replacement | |
| CN101161293A (en) | Resist calcification modified method of heterogeneity biological organization material | |
| US20230218803A1 (en) | Valve Material With Combined Anti-Clotting And Anti-Calcification Properties And Preparation Method Therefor | |
| CN205095072U (en) | Artificial biological blood vessel with valve | |
| CN107961397A (en) | Implant and the method for producing implant | |
| WO2010139209A1 (en) | Kit used for obtaining whole liver scaffold and method for obtaining whole liver scaffold | |
| CN105903071A (en) | Cornea scaffold material and preparation method thereof and 3D printing method of cornea scaffold | |
| CN111701077B (en) | Valve with antithrombotic and anticalcification functions and preparation method and application thereof | |
| CN105233341A (en) | Artificial biological valved blood vessel and preparation method thereof | |
| CN204121199U (en) | A kind of artificial bio-membrane is with valve blood vessel | |
| CN102895702A (en) | Composite manual bile duct and preparation method thereof | |
| CN103861158B (en) | Preparation method of silk fibroin and sulfated silk fibroin composite tubular scaffold | |
| CN104874020A (en) | A preparing method of a small-intestine decellularized scaffold with a complete three-dimensional structure and a vascular network | |
| CN112043876B (en) | Reproducible and repairable vascular stent covering film and preparation method thereof | |
| CN108744063A (en) | A kind of degradable artificial endocranium and preparation method thereof | |
| CN100478037C (en) | A fabric enhanced composite vascular prosthesis | |
| CN110368526A (en) | A kind of medical acellular organism material and preparation method thereof | |
| CN112915260B (en) | Non-glutaraldehyde cross-linked biomaterial and preparation method thereof | |
| CN108404211A (en) | A kind of Preparation method and use of hepatic tissue inductivity hydrogel material | |
| CN201333112Y (en) | Non-support heterologous bioprosthetic heart valve |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 101312 No.5, Zhuyuan 2nd Street, Shunyi District, Beijing (Tianzhu Comprehensive Bonded Zone) Patentee after: Beijing medipeak Medical Technology Co.,Ltd. Address before: 101312 No.5, Zhuyuan 2nd Street, Shunyi District, Beijing (Tianzhu Comprehensive Bonded Zone) Patentee before: BEIJING MED ZENITH MEDICAL SCIENTIFIC Co.,Ltd. |